Novel TYK2 inhibitor D-2570 in moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase 2 trial

Journal:

Journal of the American Academy of Dermatology

Published:

2025-09-18

DOI:

10.1016/j.jaad.2025.09.036

Affiliations:

26

Authors:

28

Go to article

Institutions	Authors	Share
InventisBio, China	3.000000	0.11
Peking University People's Hospital, PKUHSC, China	2.000000	0.07
Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital (SAMSPH), China	1.000000	0.04
Shandong Provincial Hospital, China	1.000000	0.04
Beijing Tongren Hospital, Capital Medical University, China	1.000000	0.04
Beijing Friendship Hospital, Capital Medical University, China	1.000000	0.04
Wuxi No.2 People's Hospital, China	1.000000	0.04
Shenzhen People’s Hospital, China	1.000000	0.04
Affiliated Hospital of Hebei Engineering University, China	1.000000	0.04
Sun Yat-sen Memorial Hospital, SYSU, China	1.000000	0.04
Shiyan Renmin Hospital, China	1.000000	0.04
Southern Medical University (SMU), China	1.000000	0.04
The First Hospital of Jilin University, China	1.000000	0.04
Shanghai Tenth People's Hospital, Tongji University, China	1.000000	0.04
Henan Provincial People's Hospital, China	1.000000	0.04
Affiliated Hospital of Chengde Medical University, China	1.000000	0.04
The First People's Hospital of Hangzhou, China	1.000000	0.04
Nanyang the First People's Hospital, China	1.000000	0.04
Peking University Third Hospital (PUTH), PKUHSC, China	1.000000	0.04
The First Affiliated Hospital of Bengbu Medical University, China	1.000000	0.04
The First Hospital of Hebei Medical University, HEBMU, China	1.000000	0.04
Affiliated Hospital of Guilin Medical University, China	1.000000	0.04
First People's Hospital of Chenzhou, XNU, China	1.000000	0.04
Jiujiang University Affiliated Hospital, China	1.000000	0.04
Renmin Hospital of Wuhan University/Hubei General Hospital, China	1.000000	0.04

Interested in Clinical Sciences?